| Literature DB >> 22778765 |
Chika Ohata1, Norito Ishii, Takahiro Hamada, Yutaka Shimomura, Hironori Niizeki, Teruki Dainichi, Minao Furumura, Daisuke Tsuruta, Takashi Hashimoto.
Abstract
We reviewed all 91 Japanese dermatitis herpetiformis (DH) patients reported over the last 35 years. The male-to-female ratio was 2 : 1. The mean age at onset was 43.8, and 13 years earlier for female patients. More than half of these Japanese DH patients showed granular IgA deposition in the papillary dermis, and another one-third showed fibrillar IgA deposition. The male patients with granular IgA deposition were 10 years older than those with fibrillar deposition. Whereas patients with granular IgA deposition showed typical distribution of the skin lesions, the predilection sites of DH tended to be spared in patients with fibrillar IgA deposition. Only 3 patients had definite gluten-sensitive enteropathy. There was a statistical difference in the frequency of human leukocyte antigen (HLA)-DR9 between the granular group and controls among Japanese. No patients had HLA-DQ2 or -DQ8, which is frequently found in Caucasian DH patients. The absence of HLA-DQ2/DQ8, the inability to identify celiac disease in most cases, the predominance of fibrillar IgA, and the unusual distribution of clinical lesions in Japanese patients suggest that Japanese DH may be a subset of DH patients and have a pathogenesis which is different from that currently proposed in Caucasian DH patients.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22778765 PMCID: PMC3385876 DOI: 10.1155/2012/562168
Source DB: PubMed Journal: Clin Dev Immunol ISSN: 1740-2522
Clinical characteristics of 91 patients.
|
| ||
|---|---|---|
| Gender | ||
| Male | 61/91 | |
| Female | 30/91 | |
| Age at the initial visit, mean ± SD (range), years | 46.6 ± 19.9/91 | (1–87) |
| Male | 51.5 ± 20.5/61 | (1–87) |
| Female | 36.8 ± 14.1/30 | (18–72) |
| Age at onset, mean ± SD (range), years | 43.8 ± 18.6/75 | (1–87) |
| Male | 48.5 ± 19.6/48 | (1–87) |
| Female | 35.3 ± 13.0/27 | (14–72) |
| Site of lesion | ||
| Elbow | 33/84 | (39.3%) |
| Knee | 29/84 | (34.5%) |
| Buttock | 30/84 | (35.7%) |
| Elbow and/or knee and/or buttock | 37/84 | (44.0%) |
| Face | 11/84 | (13.1%) |
| Ear | 9/84 | (10.7%) |
| Neck | 8/84 | (9.5%) |
| Scalp | 6/84 | (7.1%) |
| Groin | 4/84 | (4.8%) |
| At least one predilection site | 49/84 | (58.3%) |
| Extremities* | 41/84 | (48.8%) |
| Trunk** | 55/84 | (65.5%) |
| Whole body*** | 6/84 | (7.1%) |
| IgA deposition in the papillary dermis | ||
| Granular | 50/91 | (54.9%) |
| Fibrillar | 33/91 | (36.3%) |
| Granular and fibrillar | 7/91 | (7.7%) |
| Cluster | 1/91 | (1.1%) |
| Other deposition in the papillary dermis | ||
| C3 | 20/91 | (22.0%) |
| IgG | 9/91 | (9.9%) |
| IgM | 4/91 | (4.4%) |
| Fibrinogen | 2/91 | (2.2%) |
| GSE | 3/91 | (3.3%) |
| Jejunum mucosa biopsy | ||
| Villous atrophy**** | 3/6 | (50.0%) |
| No change***** | 3/6 | (50.0%) |
| Associated diseases | ||
| Diabetes mellitus | 8/91 | (8.8%) |
| Lymphoma | 3/91 | (3.3%) |
| Thyroid disease | 1/91 | (1.1%) |
| Sjögren syndrome | 1/91 | (1.1%) |
| HLA antigen§ | ||
| DR4 | 13/31 | (41.9%)# |
| DR9 | 15/31 | (48.4%)## |
| Other antibodies | ||
| Antireticulin antibodies | 0/9 | (0.0%) |
| Antigliadin antibodies | 0/3 | (0.0%) |
| Antiendomysial antibodies | 0/3 | (0.0%) |
| Anti-tTG IgA antibodies | 0/2 | (0.0%) |
| Anti-eTG IgA antibodies | 2/2 | (100.0%) |
| Therapy | ||
| Dapsone | 62/82 | (75.6%) |
| Dapsone + gluten-free diet | 7/82 | (8.5%) |
| Gluten-free diet + topical steroid | 1/82 | (1.2%) |
| Topical steroid | 9/82 | (11.0%) |
| Others† | 3/82 | (3.7%) |
*Not including cases limited only to elbow or knee; **not including cases limited only to buttock, neck, or groin; ***not including cases limited to combination of predilection sites; ****including 1 patient with GSE; *****no patients had GSE; GSE: gluten-sensitive enteropathy; tTG: tissue transglutaminase, eTG: epidermal transglutaminase; †including minocycline and topical steroid, salazosulfapyridine, and zinc oxide ointment; §frequency in HLA antigens of control was depicted from [90]. # P = 0.9, ## P = 0.007, corrected P = 0.07.
Comparison of granular and fibrillar deposition groups.
| Granular ( | Fibrillar ( |
| ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Gender | ||||||
| Male | 33/50 | (66.0%) | 22/33 | (66.7%) | ||
| Female | 17/50 | (34.0%) | 11/33 | (33.3%) | ||
| Age at the initial visit, mean ± SD (range), years | 47.2 ± 20.1/50 | (1–86) | 43.8 ± 18.0/33 | (16–78) |
| |
| Male | 53.1 ± 19.5/33 | (1–86) | 45.9 ± 20.2/22 | (16–78) |
| |
| Female | 35.9 ± 15.9/17 | (18–72) | 39.6 ± 11.4/11 | (22–68) |
| |
| Age at onset, mean ± SD (range), years | 44.4 ± 18.2/42 | (1–73) | 39.7 ± 16.0/25 | (12–74) |
| |
| Male | 50.3 ± 17.0/26 | (1–73) | 40.9 ± 19.4/16 | (12–74) |
| |
| Female | 34.9 ± 15.9/16 | (14–72) | 37.7 ± 5.7/9 | (29–50) |
| |
| Site of lesion | ||||||
| Elbow | 23/46 | (50.0%) | 5/30 | (16.7%) | ||
| Knee | 20/46 | (43.5%) | 5/30 | (16.7%) | ||
| Buttock | 25/46 | (54.3%) | 4/30 | (13.3%) | ||
| Elbow and/or knee and/or buttock | 30/46 | (65.2%) | 7/30 | (23.3%) | ||
| Face | 8/46 | (17.4%) | 3/30 | (10.0%) | ||
| Ear | 7/46 | (15.2%) | 2/30 | (6.7%) | ||
| Neck | 3/46 | (6.5%) | 5/30 | (16.7%) | ||
| Scalp | 5/46 | (10.9%) | 1/30 | (3.3%) | ||
| Groin | 4/46 | (8.7%) | 0/30 | (0.0%) | ||
| At least one predilection site | 36/46 | (78.3%) | 12/30 | (40.0%) | ||
| Extremities* | 20/46 | (43.5%) | 17/30 | (56.7%) | ||
| Trunk** | 27/46 | (58.7%) | 22/30 | (73.3%) | ||
| Whole body*** | 3/46 | (6.5%) | 3/30 | (10.0%) | ||
| Other deposition in the papillary dermis | ||||||
| C3 | 13/50 | (26.0%) | 4/33 | (12.1%) | ||
| IgG | 5/50 | (10.0%) | 4/33 | (12.1%) | ||
| IgM | 3/50 | (6.0%) | 1/33 | (3.0%) | ||
| Fibrinogen | 2/50 | (4.0%) | 0/33 | (0.0%) | ||
| Small bowel disease | 3/50 | (6.0%) | 1/33 | (3.0%) | ||
| Associated diseases | ||||||
| Diabetes mellitus | 5/50 | (10.0%) | 2/33 | (6.1%) | ||
| Lymphoma | 3/50 | (6.0%) | 0/33 | (0.0%) | ||
| Thyroid disease | 0/50 | (0.0%) | 1/33 | (3.0%) | ||
| Sjögren syndrome | 1/50 | (2.0%) | 0/33 | (0.0%) | ||
| HLA antigen§ | ||||||
| DR4 | 4/14 | (28.6%)# | 8/13 | (61.5%)## | ||
| DR9 | 9/14 | (64.3%)¶ | 3/13 | (23.1%)¶¶ | ||
*Not including cases limited only to elbow or knee; **not including cases limited only to buttock, neck, or groin; ***not including cases limited to combination of predilection sites; §frequency in HLA antigens of control was depicted from [90]. # P = 0.3 (versus controls), P = 0.09 (versus Fibrillar); ## P = 0.2 (versus controls), ¶ P = 0.002 (versus controls, corrected P = 0.02), P = 0.03 (versus Fibrillar), ¶¶ P = 0.8 (versus controls).